Cristina Jorge

Cristina Jorge

Auto-generated profile, based on publicly available information

Cristina Jorge

Nephrology Department, Unidade Local de Saúde São José, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2026 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
DSDiana Santos
Diana Santos
MLMiguel Brito Lança
Miguel Brito Lança
DNDavid Navarro
David Navarro
PBPedro Baltazar
Pedro Baltazar
CJCristina Jorge
Cristina Jorge
NFNuno Moreira Fonseca
Nuno Moreira Fonseca
Primary hyperoxaluria type 3 is a rare autosomal recessive disorder caused by HOGA1 mutations, leading to recurrent calcium oxalate nephrolithiasis. Diagno

24 March 2025 in Bulletin de la Dialyse à Domicile
Verified
Journal Article
Open access
PDF file
PSPilar Burillo Simões
Pilar Burillo Simões
ACAndreia Curto
Andreia Curto
JMJoana Marques
Joana Marques
VFVasco Fernandes
Vasco Fernandes
AFAna Carina Ferreira
Ana Carina Ferreira
CJCristina Jorge
Cristina Jorge
Dialysate leakage is a complication of peritoneal dialysis with a 5% incidence rate. Late leaks are rare, and symptoms are subtle, as fluid loss occurs most often through abdominal wall defects. An 83-year-old diabetic woman was started on automated peritoneal dialysis one month after catheter placement. Three years later, the patient complained of tiredness, peripheral edema, and abdominal pressure. Inspection showed local erythema and orange-peel skin. A computed tomography scan showed periumbilical drainage, suggesting a peritoneal leak. The patient was referred for surgery, which found a 5 mm aponeurotic defect; a herniorrhaphy was performed. The patient resumed her usual treatments without further complications. Dialysate leaks may lead to discontinuation of peritoneal dialysis. The clinical presentation can be insidious, as in this case. Active surveillance was pursued, and the patient was managed without the need for temporary switching to hemodialysis.

14 June 2023 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
HVHelena Vidal
Helena Vidal
MMMaria Do Mar Menezes
Maria Do Mar Menezes
NFNuno Moreira Fonseca
Nuno Moreira Fonseca
CJCristina Jorge
Cristina Jorge
Typical Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy (TMA) characterized by the triad of acute renal failure, hemolytic anemia and thrombocytopenia. TMAs are classified into: Inherited or primary acquired (atypical HUS), secondary or infection associated. Infection with Shiga-toxin–producing Escherichia coli (E. coli), mainly of serotype O157:H7, is the most common cause of typical HUS, but other serotypes have been rarely associated such as Enteroagregative Escherichia coli (EAEC) serotype O104:H4. Case Report We report a case of a 51-years-old male with past medical history of arterial hypertension (treated with Perindopril) and IgGk Multiple Myeloma (MM) diagnosed 10 years prior submitted to two bone marrow autotransplants (9 and 4 years prior) and multiple chemotherapy agents including Carfilzomib-Pomalidomide-Dexamethasone (last cycle 4 days before the onset of symptoms). One week after returning from a trip to Brazil, he was admitted to the emergency department with a two-day history of non-bloody diarrhea (4-5 liquid stools per day) and asthenia, with similar positive familiar epidemiology. He denied abdominal pain, fever, nausea or vomiting. At physical examination, he was hypertensive (177/90 mmHg), anuric (12,5 ml/h), dehydrated and apyretic. Abdominal palpation was painless and there were no signs of peritoneal irritation. Laboratory tests showed hemoglobin 10.5 g/dl, new onset thrombocytopenia (261 000/uL » 21 000/uL), kidney disfunction (serum creatinine (sCr) 0.74 mg/dL to 9 mg/dL and serum urea (sU) 41 mg/dL to 260 mg/dL), hyperkaliemia (6 mEq/L) and metabolic acidosis (pH 7,39 and bicarbonate 18.4 mEq/L). LDH was 1949 U/L, C-reactive protein 30.6 mg/L, procalcitonin 3.77 ng/mL, haptoglobin <0.07 g/L and with normal complement levels (C3 and C4). Schistocytes were present in peripheral blood smear. The diagnosis of Acute Kidney Injury related with TMA was established and the patient was transferred to the Nephrology ward and urgent hemodialysis was started. Exhaustive study was performed showing normal renal ultrasound, non-nephrotic proteinuria (1.6 g/g), urinalysis showed leukocyturia and erythrocyturia. Autoimmune study including PR3-ANCA, MPO-ANCA, anti-GBM antibody, Anti-dsDNA antibody, anti-beta 2-glycoprotein I antibodies, anticardiolipin antibodies, anti-ADAMTS13 antibodies and ADAMTS13 activity, as well as study of complement C5, C'3, C'4, factor B, H and I, anti-factor H ac, AH 50 and CH50b were unremarkable. Blood and urine culture and antistreptolysin O titers were negative. Specific stool cultures for E. coli O157, Shigella, Salmonella, Yersinia and Campylobacter were negative. Stool evaluation for parasites were also negative. Viral serology for HIV, HBV, HCV and Plasmodium tests were negative. PCR stool was required due to high suspicion of E.coli infection. The suspicion of a Carfilzomib induced TMA was also raised, while molecular techniques results were awaited. MM was stable and treatment was held until recovery of kidney function. During hospitalization the patient recovered diuresis and creatinine decreased. On the 11th day of hospitalization, he was discharged but still depended on hemodialysis. Finally, stool PCR techniques identified aatA and aggR genes associated with EAEC O104:H4 allowing the diagnosis of acquired infectious HUS rather than drug-related TMA. One week after discharge, the dialysis was stopped due to sCr 3 mg/dL. Four months later, he resumed Carfilzomib and kidney function remained stable with sCr 0.9 mg/dL, despite sustained proteinuria of 1.2 g. The authors emphasize the importance of considering other causes of TMA when E.coli O157 infection is excluded, namely drug-related causes (as Carfilzomib) or less frequent infectious agents such as EAEC O104:H4. This case reveals the importance of requesting PCR in the stool even when the E.coli test is negative. This is of particular relevance in immunosuppressed patients. This diagnosis allowed continuing MM treatment.

3 February 2025 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
BBBárbara Beirão
Bárbara Beirão
HBHenrique Borges
Henrique Borges
JMJoana Trigo Medeiros
Joana Trigo Medeiros
FRFilipa Fonte Rodrigues
Filipa Fonte Rodrigues
APAna Pena
Ana Pena
CJCristina Jorge
Cristina Jorge
Background: Time-zero biopsies (TzB) provide insights into donor-derived lesions, but their predictive value for long-term outcomes remains uncertain. We aimed to identify clinical and histological factors from TzB of deceased donors influencing glomerular filtration rate (GFR) at 3- and 5-year post-transplantation. Methods: We retrospectively analyzed TzB performed from January 2015 to August 2019. Nineteen biopsies were excluded due to recipient death before 3 years. We examined donor and recipient-related characteristics and histological findings categorized using the Banff scoring system. Results: Among 147 biopsies, 61.9% of donors were male, with a mean age of 51.8 ± 13.5 years, and 27.2% met expanded criteria. Histologic analysis revealed 44.2% had alterations in the Banff chronic scoring system: 29.1% in vascular fibrous intimal thickening (Cv), 26.6% in arteriolar hyalinosis (Ah), and 8.3% in interstitial fibrosis (Ci)/tubular atrophy (Ct). Mean GFR was 54.8 ± 21.2 and 52.3 ± 23.0 mL/min/1.73 m2 at 3 and 5 years, respectively. At 3 years, Ah > 0, Ci/Ct > 0, Cv > 0, Banff chronic sum score > 0, glomerulosclerosis (GE), donor age > 50 years, expanded criteria donors, and rejection episodes were significantly associated with lower GFR. With the exception of Ci/Ct, all other parameters were also significantly associated with lower GFR at 5 years. Linear regression indicated donor age [β (95%CI) = -0.257 (-0.783, -0.021); p = 0.039] and arteriolar hyalinosis [β (95%CI) = -0.207 (-16.767, -0.448); p = 0.039]; p = 0.039) as predictors of GFR at 3 years, with donor age maintaining predictive value at 5 years [β (95%CI) = -0.276 (-0.776, -0.137); p = 0.006]. A tendency towards predictive value for GFR at 5 years was noted for GE [β (95%CI) = -0.198 (120.0, 1.038); p = 0.054]. Conclusion: TzB provide valuable prognostic information for long-term graft function with histological findings (particularly arteriolar hyalinosis and GE) and donor age serving as significant predictors of GFR at 3 and 5 years post-transplantation. These findings suggest TzB can be useful for risk stratification and personalized management of KT recipients.

30 July 2023 in Portuguese Journal of Nephrology & Hypertension
Verified
Journal Article
Closed access
CJCristina Jorge
Cristina Jorge
CNCentro Hospitalar Universitário de Lisboa Central – Hospital Curry Cabral Serviço de Nefrologia
Centro Hospitalar Universitário de Lisboa Central – Hospital Curry Cabral Serviço de Nefrologia

12 January 2024 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
APAna Piedade
Ana Piedade
HVHelena Vidal
Helena Vidal
PSPilar Simões
Pilar Simões
Miguel Bigotte VieiraMiguel Bigotte Vieira
Miguel Bigotte Vieira
MCMaria Jesus de Jesus Fernandes Chasqueira
Maria Jesus de Jesus Fernandes Chasqueira
CJCristina Jorge
Cristina Jorge
Human cytomegalovirus (CMV ) infection is the most prevalent infection affecting organ transplant recipients, and it is a cause of morbidity and mortality in patients undergoing kidney transplantation. "e introduction of ganciclovir (GCV ) for both prophylaxis and treatment has vastly improved patient outcomes. GCV resistance can be caused by mutations in the UL97 phosphotransferase gene or the UL54 polymerase gene. It occurs in 1 to 2% of kidney transplant recipients with CMV infection or disease. Antiviral resistance should be considered when increased viral loads and disease progression are observed despite the administration of adequate antiviral therapy. "e degree of resistance varies depending on the type of mutation present. We report a patient with resistance to GCV due to a UL97 del597-599 mutation who, despite typically requiring an 8-fold increase in GCV dose, showed a signi#cant decrease in viral load with just a double dose increase. However, the patient’s overall clinical course remained complicated. Due to severe leukopenia, maribavir had to be started, with a good response. Nevertheless, he ultimately died due to indirect CMV-related complications. "is case also highlights the complexity of transplant patients, who present multiple challenges ranging from infections to therapy management.